Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 110

Sort by

Sort Order Select

Journal Articles

ASXL1 Mutations Are Associated with Widespread and Distinct DNA Methylation Alterations

Nora E Rahmani, MD, Nandini Ramachandra, Tushar D Bhagat, PhD, Shanisha Gordon, Kith Pradhan, PhD, Bianca Rivera Pena, Mohammad Kazemi, Orsi Giricz, PhD, Shahina Maqbool, Raul Olea, Hamid Dolatshad, Vickram Tittrea, Dharamveer Tatwavedi, Shalini Singh, Andrea Pellagatti, Jacqueline Boultwood, Amit Verma, MBBS

Blood (2019) 134 (Supplement_1): 2989.

https://doi.org/10.1182/blood-2019-126850

Published: 2019

Journal Articles

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, MD PhD, J. Elizabeth Pease, PhD, Giovanna Pomilio, Veronique Litalien, Jon Travers, PhD, Andrew H. Wei

Blood (2019) 134 (Supplement_1): 3930.

https://doi.org/10.1182/blood-2019-129564

Published: 2019

Journal Articles

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

Aksinija A Kogan, BS, MS, Lena J Mclaughlin, BS, Maria R. Baer, MD, Stephen Baylin, MD, Michael Topper, BS, Feyruz V. Rassool, BSc, PhD

Blood (2019) 134 (Supplement_1): 3763.

https://doi.org/10.1182/blood-2019-129535

Published: 2019

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Abnl Marro : An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes

Michael R. Savona, MD, Pierre Fenaux, MD PhD, Eric Padron, MD, Mrinal M Patnaik, MDMBBS, Uwe Platzbecker, MD, Adam Seegmiller, MD PhD, Raphael Itzykson, MD PhD, Guillermo F. Sanz, MD PhD, Valeria Santini, MD, Eric Solary, MD PhD

Blood (2019) 134 (Supplement_1): 4273.

https://doi.org/10.1182/blood-2019-130722

Published: 2019

Journal Articles

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Hongyan Tong, Docter, Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, MD, Shengyun Lin, Yuefeng Zhuang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 2594.

https://doi.org/10.1182/blood-2019-127675

Published: 2019

Journal Articles

Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine Model

Haley E. Ramsey, PhDMSc, Maria Arrate, MSc, Londa Fuller, Agnieszka E. Gorska, MSc, Kelli Boyd, DVM, PhD, Melissa A. Fischer, MSc, PhD, Aram Oganesian, PhD, Mohammad Azab, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1376.

https://doi.org/10.1182/blood-2019-125899

Published: 2019

Journal Articles

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

Brianna N Smith, MD MS, Dan Cojocari, PhD BSc, Julie J Purkal, MA, Maria Arrate, MSc, Haley E. Ramsey, PhDMSc, Joel D. Leverson, PhD, Erwin Boghaert, MS, MD, Darren C. Phillips, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1380.

https://doi.org/10.1182/blood-2019-123068

Published: 2019

Journal Articles

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

Katsuyoshi Takata, MD PhD, Lauren C. Chong, MSc, Avinash Thakur, PhD, Tomohiro Aoki, MD PhD, Anja Mottok, MD PhD, Elizabeth Chavez, BSc, Cg RT, Pedro Farinha, MD PhD, Graham W Slack, MD, Pamela Hoodles, Sohrab P Shah, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 1509.

https://doi.org/10.1182/blood-2019-129730

Published: 2019

Journal Articles

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Stephen P. Ducray, BSc, Ricky Trigg, PhD, Andrew J. Bannister, PhD, Raymond Lai, MD PhD FRCP, Gerda Egger, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Suzanne Turner, PhD

Blood (2019) 134 (Supplement_1): 1483.

https://doi.org/10.1182/blood-2019-125648

Published: 2019

Journal Articles

Oral Vitamin C Supplementation to Azacitidine in Patients with Myeloid Cancer: Normalization of Plasma Vitamin C Induces Epigenetic Changes

Linn Gillberg, MSc, PhD, Andreas Due Ørskov, MD, Ammar Nasif, MSc, Hitoshi Otani, PhD, Zachary Madaj, MSc, Jakob Werner Hansen, MD, Johanne Bay Mogensen, MSc, PhD, Minmin Liu, MSc, PhD, Inge Høgh Dufva, MD, Lykkesfeldt Jens, MSc, PhD, Petra Hajkova, Professor, PhD, Peter A. Jones, Professor, PhD DSc (hon), Kirsten Grønbæk, Professor, MD DMSc

Blood (2018) 132 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2018-99-111525

Published: 2018

Journal Articles

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Aksinija A Kogan, BS, MS, Michael Topper, BS, Susannah C Shissler, BS, Michael S Lee, BS, Dominique R Bollino, BS, Eun Yong Choi, Rena G Lapidus, PhD, Li Li, MD PhD, Donald Small, MD PhD, Maria R. Baer, MD, Tonya J Webb, PhD, Stephen Baylin, MD, Feyruz V. Rassool, BSc, PhD

Blood (2018) 132 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2018-99-117294

Published: 2018

Journal Articles

Disulfiram May Contribute to Apoptosis of Myeloma Cells By Reactivating of Cell Cycle Regulating Gene CDKN2A

Denisa Hrckova Drozdkova, Jan Gursky, PhD, Petra Luzna, Sabina Sevcikova, PhD, Jiri Minarik, MD PhD, Katerina Smesny Trtkova, PhD

Blood (2018) 132 (Supplement 1): 5125.

https://doi.org/10.1182/blood-2018-99-114743

Published: 2018

Journal Articles

The Effect of TET Mutations on DNA Methyltransferase Cytotoxicity and ERV Induction in B and T Cell Malignancies

Juan Carlos Nogues, BS, Zi Michael Wang, BS, Sarah School Chisholm, MA, Mitcell Smith, MD PhD, Eduardo Sotomayor, MD, Katherine Chiappinelli, PhD

Blood (2018) 132 (Supplement 1): 5157.

https://doi.org/10.1182/blood-2018-99-120281

Published: 2018

Journal Articles

Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients

Xi Yang, Hong Zheng, MD PhD, Jingying Dai, PhD, Chenglong Li, MDand PhD, Rong Zhang, MD PhD, Xiaodong WANG, MD, Chunsen Wang, MD, Xiaobing Huang

Blood (2018) 132 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2018-99-111671

Published: 2018

Journal Articles

The LSD1 Inhibitor RN-1 Increases γ-Globin Expression in Baboons By Targeting an Early Event Responsible for γ-Globin Repression

Kestis Vaitkus, Vinzon Ibanez, B.S., Maria Armila Ruiz, B.S., Ramasamy Jagadeeswaran, PhD, Yogenthiran Saunthararajah, MD, James Douglas Engel, PhD, Joseph DeSimone, PhD, Angela Rivers, MD, Donald Lavelle, PhD

Blood (2018) 132 (Supplement 1): 1054.

https://doi.org/10.1182/blood-2018-99-113539

Published: 2018

Journal Articles

DNA Methyltransferase Inhibitors Increase Expression of CD38 and Enhance Daratumumab Efficacy in Multiple Myeloma

Priya Choudhry, PhD, Margarette C. Mariano, MS, Arun P Wiita, MD PhD

Blood (2018) 132 (Supplement 1): 5618.

https://doi.org/10.1182/blood-2018-99-114206

Published: 2018

Journal Articles

Novel Therapeutic Targeting of UHRF1 Restores 5'-Azacytidine Response in Resistant Acute Myeloid Leukemia

Anup Kumar Singh, MS, PhD, Xiaochun Yu, MD PhD

Blood (2018) 132 (Supplement 1): 1356.

https://doi.org/10.1182/blood-2018-99-115735

Published: 2018

Journal Articles

Cooperative Effects of a Dnmt Inhibitor and All- Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara

Ruth Meier, Gabriele Greve, Christoph Niemöller, Heiko Becker, Tobias Ma, Ralitsa Langova, Björn Grüning, Lars Feuerbach, Daniel B. Lipka, Justus Duyster, Prof., Benedikt Brors, Christoph Plass, Michael Lübbert

Blood (2018) 132 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2018-99-113450

Published: 2018

NARROW

ASXL1 Mutations Are Associated with Widespread and Distinct DNA Methylation Alterations

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Abnl Marro : An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine Model

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Oral Vitamin C Supplementation to Azacitidine in Patients with Myeloid Cancer: Normalization of Plasma Vitamin C Induces Epigenetic Changes

The Combination of PARP Inhibitors and DNMT Inhibitors Modulates Immune Activity and Suggests a Role for Immune Therapy in AML

Disulfiram May Contribute to Apoptosis of Myeloma Cells By Reactivating of Cell Cycle Regulating Gene CDKN2A

The Effect of TET Mutations on DNA Methyltransferase Cytotoxicity and ERV Induction in B and T Cell Malignancies

Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients

The LSD1 Inhibitor RN-1 Increases γ-Globin Expression in Baboons By Targeting an Early Event Responsible for γ-Globin Repression

DNA Methyltransferase Inhibitors Increase Expression of CD38 and Enhance Daratumumab Efficacy in Multiple Myeloma

Novel Therapeutic Targeting of UHRF1 Restores 5'-Azacytidine Response in Resistant Acute Myeloid Leukemia

Cooperative Effects of a Dnmt Inhibitor and All- Trans Retinoic Acid in an AML Cell Line Model Lacking PML-Rara

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only